Tredaptive (Merck Inc) fails to meet primary end point in HPS2-THRIVE Dyslipidaemia trial

Detailed results of HPS2-THRIVE, a study of Tredaptive (nicotinic acid plus laropiprant), from Merck Inc, in 25673 patients with Dyslipidaemia suggests adding Tredaptive to statin therapy did not significantly further reduce the risk of major vascular events. In the trial the composite primary endpoint of major vascular events (coronary death non-fatal heart attack stroke or any arterial revascularization) occurred in 13.2 percent of the patients taking Tredaptive plus statin therapy (n=1696) compared to 13.7 percent of the patients taking statin therapy alone (n=1758) after a median 3.9 years of follow-up.

As previously disclosed there were statistically significant increases in non-fatal serious adverse events observed in patients taking Tredaptive plus statin therapy compared to patients taking placebo plus statin therapy. Results were presented by Professor Jane Armitage FFPH FRCP professor of clinical trials and epidemiology Oxford University and the primary investigator for the HPS2-THRIVE study at he American College of Cardiology 62nd Annual Scientific Sessions.